Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag AC Immune's Parkinson's disease drug shows promising results, boosting antibodies 16 times more than placebo.

flag AC Immune has reported positive interim results from its Phase 2 trial of ACI-7104.056, an immunotherapy for early Parkinson's disease. flag The treatment showed significant increases in antibodies targeting harmful proteins in the brain, with no major safety concerns reported. flag The drug induced 16 times more antibodies than the placebo. flag AC Immune plans further trials to assess the therapy's impact on symptoms and biomarkers, potentially involving up to 150 patients.

5 Articles